Jul 10, 2025, 09:38
EHA 2025: Dr. Fathi and Dr. Koehne on Menin Inhibitors, Oral HMAs, and Post-Transplant AML Strategies
The European Hematology Association (EHA) 2025 Congress, held from June 12–15 at the Allianz MiCo Convention Center in Milan, welcomed over 10,000 participants from around the world to explore the latest advances in hematologic malignancies.
In this special episode from OncoDaily, Dr. Aleksandra Filipovic, member of EHA’s Scientific and Policy Communication Committee (SPCC), speaks with two world-leading leukemia experts:
Dr. Amir Fathi, Director of the Center for Leukemia at Massachusetts General Hospital
Dr. Guenther Koehne, Deputy Director and Chief of Hematologic Oncology and Bone Marrow Transplant at Miami Cancer Institute
Together, they discuss emerging data and future directions in acute myeloid leukemia (AML) treatment, including:
- Breakthroughs with menin inhibitors (revumenib, ziftomenib) in NPM1-mutated and KMT2A-rearranged AML
- Growing role of oral hypomethylating agents (HMAs) combined with venetoclax for outpatient care
- Next-generation triplet regimens aiming to improve efficacy while preserving tolerability
- Unmet needs and novel approaches in TP53-mutated and high-risk AML
- Challenges and potential solutions for post-transplant maintenance
- Key differences between U.S. and European treatment paradigms
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 10, 2025, 09:06
Jul 10, 2025, 08:52
Jul 10, 2025, 08:35
Jul 10, 2025, 08:06
Jul 10, 2025, 06:53